Day 1, Thursday, May 23rd
08:30-10:00 BCMA-targeted therapies in myeloma: the new treatment frontier
Pre-COMy IME Symposium
10:00-10:20 Coffee Break
10:20-10:30 COMy 2024 kick-off: Welcome by the Congress Co-Chairs
10:30-12:00 Session 1: Defining risk in myeloma
Moderators: Joan Bladé, Spain; Vincent Rajkumar, USA
10:30-10:45 MGUS risk stratification: Shaji Kumar, USA
10:45-11:00 Smoldering myeloma risk stratification: Irene Ghobrial, USA
11:00-11:15 Ultra high-risk disease in IMS consensus: Jill Corre, France
11:15-11:30 Genomic landscape of high-risk disease: Eileen Boyle, USA
11:30-11:45  Frailty as a risk stratifier: Ceri Bygrave, UK
11:45-12:00 Discussion: should we design risk-based protocols?
All session faculty and Hervé Avet-Loiseau, France
12:00-12:30 Lunch Break
12:30-14:00 To BCMA or not to BCMA? Addressing unanswered questions in RRMM
Industry-supported Lunch Symposium
14:00-14:10 Technical Break
14:10-15:35 Session 2: Novel approaches for disease and response assessment
Moderators: Roberto Mina, Italy; Kwee Yong, UK
14:10-14:25 Optimizing MRD assessment: Bruno Paiva, Spain
14:25-14:40 Mass spectrometry: Noemi Puig, Spain
14:40-14:55 Immune monitoring in the context of immunotherapy: Niels van de Donk, Netherlands
14:55-15:10 Advances in imaging techniques: Elena Zamagni, Italy
15:10-15:25 The microbiota signature: Florent Malard, France
15:25-15:35 Discussion: should we use MRD to guide therapy?
All session faculty and Jesús San Miguel, Spain
15:35-15:45 Technical Break
15:45-17:15 Is MRD ready for prime time for multiple myeloma patients?
Industry-supported Symposium
17:15-17:30 Coffee Break
17:30-18:30 Session 3: Precursor conditions and other plasma cell disorders
Moderators: Michel Delforge, Belgium; Irene Ghobrial, USA
17:30-17:45 Screening for MGUS: hype or reality? Sigurdur Kristinsson, Iceland
17:45-18:00 Diagnosis and management of amyloidosis: Giampaolo Merlini, Italy
18:00-18:15 Diagnosis and management of Waldenström macroglobulinemia: Steven Treon, USA
18:15-18:30 Discussion: should we treat precursor conditions?
All session faculty and Bertrand Arnulf, France & Fredrik Schjesvold, Norway
18:30-19:15 Session 4: Plenary lectures
Chairs: Holger Auner, Switzerland; Charlotte Pawlyn, UK
18:30-18:50 Genomics of myeloma: the latest advances: Nikhil Munshi, USA
18:50-19:15 Curing myeloma: from the bench to the bedside: Kenneth Anderson, USA
Day 2, Friday, May 24th
08:15-08:30 Good Morning Breakfast
08:30-09:20 Session 5: IMS Session
Chairs: Philippe Moreau, France; Nikhil Munshi, USA
08:30-08:50 MRS: a surrogate end-point: Nikhil Munshi, USA
08:50-09:10 Real-world evidence with bispecific antibodies and CAR-T: Philippe Moreau, France
09:10-09:20 Discussion
09:20-09:30 Technical Break
09:30-11:00 Harnessing the Immune System: New Emerging Data in Multiple Myeloma
Industry-supported Symposium
11:00-11:20 Coffee Break
11:20-12:30 Session 6: Frontline management of newly diagnosed myeloma
Moderators: Mario Boccadoro, Italy; Karthik Ramasamy, UK
11:20-11:35 The optimal induction prior to transplant: Francesca Gay, Italy
11:35-11:50 The role of double transplant: Hartmut Goldschmidt, Germany
11:50-12:05 The evolving landscape of maintenance therapy: Laura Rosiñol, Spain
12:05-12:20 The optimal approach in very old and frail patients: Thierry Facon, France
12:20-12:30 Discussion: should we continue to transplant myeloma?
All session faculty and Michele Cavo, Italy & Katja Weisel, Germany
12:30-13:00 Lunch Break
13:00-14:30 More choices, more flexibility: Individualising and optimising treatment in NDMM
Industry-supported Lunch Symposium
14:30-14:45 Technical Break
14:45-15:45 Session 7: Practical management of specific situations
Chairs: Meral Beksac, Turkey; Lalit Kumar, India
14:45-15:00 Extra-medullary disease: Philippe Moreau, France
15:00-15:15 Therapy of patients under dialysis: Aurore Perrot, France
15:15-15:30 Bone disease: the latest guidelines: Evangelos Terpos, Greece
15:30-15:45 Vaccinations and infectious prophylaxis: Heinz Ludwig, Germany
15:45-16:00 Coffee Break
16:00-17:30 Going for Gold: Marking Strides in Multiple Myeloma Treatment Strategies
Industry-supported Symposium
17:30-17:45 Technical Break
17:45-18:45 Session 8: Plenary lectures
Moderators: Suzanne Lentzsch, USA; Saad Usmani, USA
17:45-18:00 CAR-T cells: present and future: Hermann Einsele, Germany
18:00-18:15 Bispecific antibodies: present and future: Nizar Bahlis, Canada
18:15-18:30 Minimizing toxicities after immunotherapy: Salomon Manier, France
18:30-18:45 Discussion: how to sequence immunotherapies?
All session faculty and Ajai Chari, USA & Thomas Martin, USA
18:45-19:15 COMy Award Ceremony
 Presented by the Congress Co-Chairs
 Jean-Luc Harousseau Award
Multiple Myeloma Pioneers Award
Day 3, Saturday, May 25th
08:00-08:10 Good Morning Breakfast
08:10-09:10 Session 9: Novel agents under development
Chairs: Michael O’Dwyer, Ireland; Rakesh Popat, UK
08:10-08:25 CELMODs: Sagar Lonial, USA
08:25-08:40 Antibody-drug conjugates: Fredrik Schjesvold, Norway
08:40-08:55 Peptide conjugates: Enrique Ocio, Spain
08:55-09:10 How to bridge patients prior to CAR-T cells? Paul Richardson, USA
09:10-09:20 Technical Break
09:20-10:50 Is there a place for BCMA-based combinations in early RRMM?
Industry-supported Symposium
10:50-11:10 Coffee Break
11:10-12:30 Session 10: How I treat a relapsed/refractory myeloma
Moderators: Bhagirathbhai Dholaria, USA; Joseph Mikhael, USA
11:10-11:25 Clinical case presentation + Treatment options (1st relapse after transplant):
Cyrille Touzeau, France
11:25-11:40 Clinical case presentation + Treatment options (1st relapse after anti-CD38+Rd):
Alessandra Larocca, Italy
11:40-11:55 Clinical case presentation + Treatment options (triple class refractory young patient):
Xavier Leleu, France
11:55-12:10 Clinical case presentation + Treatment options (triple class refractory elderly patient):
Hira Mian, Canada
12:10-12:30 Discussion
All session faculty and Claudio Cerchione, Italy & Joshua Richter, USA
12:30-13:00 Lunch Break
13:00-14:00 An innovative therapeutic option in the treatment of triple-class exposed relapsed refractory multiple myeloma (TCE RRMM)
Industry-supported Lunch Symposium
14:00-14:10 Technical Break
14:10-14:55 Management of triple-class refractory patients in the absence of immunotherapies
Chairs: Mohamad Mohty, France; Lisa Leypoldt, Germany
14:10-14:25 Case study presentation: Bhagirathbhai Dholaria, USA
14:25-14:40 XPO-1 inhibition for refractory myeloma: Lisa Leypoldt, Germany
14:40-14:55 Discussion
14:55-16:10 Session 11: The road to cure: future protocols and directions
Chairs: Jean-Luc Harousseau, France; Vincent Rajkumar, USA
14:55-15:10 Young and fit patients: Pieter Sonneveld, Netherlands
15:10-15:25 Elderly and/or frail patients: Sonja Zweegman, Netherlands
15:25-15:40 Protocols for low- and middle-income countries: Vania Hungria, Brazil
15:40-15:55 How to design the best protocol? Jean-Luc Harousseau, France
15:55-16:10 Patients’ perspective and advocacy: Brian Durie, USA
16:10-16:30 Coffee Break
16:30-17:30 Expanding Frontline Frontiers in MM: Insights on Delivering Modern Care With Innovative CD38 Quadruplet Platforms
CME Symposium
17:30-17:40 Technical Break
17:40-18:10 Session 12: Plenary lecture
Chairs: Congress Co-Chairs
17:40-18:10 New mechanisms of disease resistance to T cell-based therapies: Paola Neri, Canada
18:10-18:20 In-Person Conclusions: Summary by the Congress Co-Chairs
Day 4 (ONLINE ONLY), Sunday, May 26th
10:00-11:15 Multiple Myeloma communications I
Chairs: Mohamad Mohty, France; Arnon Nagler, Israel
10:00-10:15 EFFICACY OF MELFLUFEN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND MUTATED OR DELETED TP53
Caroline Heckman, Finland
10:15-10:30 OUTCOMES OF PATIENTS WITH EXTRAMEDULLARY DISEASE IN TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE LOCOMMOTION + MOMMENT STUDIES
Philippe Moreau, France
10:30-10:45 EFFICACY AND SAFETY OF DARATUMUMAB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE-RISK OR HIGH-RISK SMOLDERING MULTIPLE MYELOMA (SMM): FINAL ANALYSIS OF THE PHASE 2 CENTAURUS STUDY
Hartmut Goldschmidt, Germany
10:45-11:00 PHASE 2 CARTITUDE-2 UPDATE: CILTACABTAGENE AUTOLEUCEL IN MULTIPLE MYELOMA AND 1–3 PRIOR LINES (COHORT A) AND WITH EARLY RELAPSE AFTER FRONTLINE TREATMENT (COHORT B)
Michel Delforge, Belgium
11:00-11:15 Discussion
11:15-11:30 Short Break
11:30-12:30 Transforming Progress into Action in Relapsed/Refractory Multiple Myeloma: Improving Patient Outcomes Through Innovative Bispecific Antibodies
Virtual CE Symposium
12:30-13:45 Multiple Myeloma communications II
Chairs: Mohamad Mohty, France; Arnon Nagler, Israel
12:30-12:45 UPDATED RESULTS OF TALQUETAMAB, A GPRC5D×CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WITH PRIOR EXPOSURE TO T-CELL REDIRECTING THERAPIES: RESULTS OF THE PHASE 1/2 MonumenTAL-1 STUDY
Philippe Moreau, France
12:45-13:00 SELINEXOR, IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE IN FUNCTIONALLY HIGH-RISK MULTIPLE MYELOMA: RESULTS FROM THE MYELOMA DEVELOPING REGIMENS USING GENOMICS (MYDRUG) SUB-PROTOCOL Y3
Joshua Richter, USA
13:00-13:15 THE RISING UNMET NEED FOR MULTIPLE MYELOMA PATIENTS AFTER FIRST-LINE TREATMENT WITH DRD: AN EPIDEMIOLOGICAL ESTIMATE IN ITALY BETWEEN 2024-2028
Francesca Fiorentino, Italy
13:15-13:30 LINVOSELTAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-TARGETED T-CELL-ENGAGING BISPECIFIC ANTIBODY, INDUCES DEEP AND DURABLE RESPONSES IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) INCLUDING DIFFICULT-TO-TREAT SUBGROUPS
Presenter: Sundar Jagannath, USA
Joining the discussion: Naresh Bumma, USA
13:30-13:45 Discussion
13:45-14:15 Final Panel Discussion and Conclusion